We developed and characterised a robust murine breast cancer model system that is suitable for CAIX studies in vitro and in vivo—it comprises both CAIX‐positive and CAIX‐negative controls and provides a solid platform for the comprehensive preclinical assessment of CAIX‐targeted therapeutic strategies or novel imaging agents. This evidence concerns the gene CA9 and breast carcinoma.